Delving into the Latest Updates on Provid Pharmaceuticals, Inc. with Synapse

作者: Andreeff, Michael ; Al-Mulla, Fahd ; Olson, Gary L. ; Lim, Bora ; Zhou, Lanlan ; Borthakur, Gautam ; Stein, Mark ; Dicker, David T. ; Wu, Gen Sheng ; Allen, Joshua E. ; Lev, Avital ; Oster, Wolfgang ; Lulla, Amriti ; Bertino, Joseph ; El-Deiry, Wafik S. ; Prabhu, Varun V. ; Kline, C. Leah B. ; Schalop, Lee ; Madhukar, Neel ; Talekar, Mala K. ; Baumeister, Marie ; Kaufman, Howard L. ; Wang, Michael L. ; Elemento, Olivier ; Nallaganchu, B. Rao ; Duvic, Madeleine ; Pottorf, Richard S. ; Benes, Cyril ; Flaherty, Keith ; Wagner, Jessica ; Stogniew, Martin ; Ishizawa, Jo

[This corrects the article DOI: 10.18632/oncotarget.11814.].

2019-09-01·Journal of Autoimmunity1区 · 医学

HLA-DR15-specific inhibition attenuates autoreactivity to the Goodpasture antigen

1区 · 医学

Article

作者: Kitching, A Richard ; Eggenhuizen, Peter J ; Sun, Yanjun ; Rao, N Bhaskara ; Holdsworth, Stephen R ; Self, Christopher R ; Olson, Gary L ; Ooi, Joshua D ; Huynh, Megan

Goodpasture's disease manifests as rapidly progressive glomerulonephritis. Current immunosuppressive treatments do not specifically target the pathological immune response and have significant side effects. Like most autoimmune diseases, the strongest genetic association is with the HLA alleles. Inheritance of HLA-DR15 confers susceptibility, and structure-function studies have shown that HLA-DR15 plays a causative role in activating autoreactive pro-inflammatory T cells. Thus, specific inhibition of HLA-DR15 would provide a targeted therapeutic approach. We hypothesised that PV-267, an HLA-DR15-specific inhibitor, would effectively block HLA-DR15 presentation of the dominant epitope, attenuate the activation of autoreactive T cells, and limit disease. Using humanised HLA-DR15 transgenic mice, α3_135-145-specific, pro-inflammatory T cell recall responses were measured using IFN-γ and IL-17A ELISPOTs and by proliferation assay. To determine if PV-267 could limit disease, experimental autoimmune anti-GBM glomerulonephritis was induced in HLA-DR15 transgenic mice (on an Fcgr2b^-/- background), and functional and histological disease endpoints were measured. PV-267 effectively inhibited α3_135-145-specific immune responses and disease development. Mice treated prior to immunization with α3_135-145 had reduced α3_135-145-specific recall responses, and limited disease by albuminuria, histological glomerular injury, IgG deposition, and inflammatory cell infiltrates. PV-267 treatment commencing after the onset of active anti-α3(IV)NC1 autoimmunity attenuated functional and histological renal injury. When treatment was administered after disease was established, PV-267 limited the severity of histological injury. In conclusion, HLA-DR15 inhibition attenuates α3(IV)NC1-specific pro-inflammatory responses and could be used as an adjunct therapy for anti-GBM disease.

2017-10-02·Cell Cycle3区 · 生物学

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

3区 · 生物学

Article

作者: Kline, Christina Leah ; Nallaganchu, Bhaskara Rao ; Oster, Wolfgang ; Benes, Cyril H. ; Ralff, Marie D. ; Prabhu, Varun V. ; Zhou, Lanlan ; Stogniew, Martin ; Olson, Gary L. ; Wagner, Jessica ; Lev, Avital ; Allen, Joshua E. ; El-Deiry, Wafik S. ; Lulla, Amriti

Anti-cancer small molecule ONC201 upregulates the integrated stress response (ISR) and acts as a dual inactivator of Akt/ERK, leading to TRAIL gene activation. ONC201 is under investigation in multiple clinical trials to treat patients with cancer. Given the unique imipridone core chemical structure of ONC201, we synthesized a series of analogs to identify additional compounds with distinct therapeutic properties. Several imipridones with a broad range of in vitro potencies were identified in an exploration of chemical derivatives. Based on in vitro potency in human cancer cell lines and lack of toxicity to normal human fibroblasts, imipridones ONC206 and ONC212 were prioritized for further study. Both analogs inhibited colony formation, and induced apoptosis and downstream signaling that involves the integrated stress response and Akt/ERK, similar to ONC201. Compared to ONC201, ONC206 demonstrated improved inhibition of cell migration while ONC212 exhibited rapid kinetics of activity. ONC212 was further tested in >1000 human cancer cell lines in vitro and evaluated for safety and anti-tumor efficacy in vivo. ONC212 exhibited broad-spectrum efficacy at nanomolar concentrations across solid tumors and hematological malignancies. Skin cancer emerged as a tumor type with improved efficacy relative to ONC201. Orally administered ONC212 displayed potent anti-tumor effects in vivo, a broad therapeutic window and a favorable PK profile. ONC212 was efficacious in vivo in BRAF V600E melanoma models that are less sensitive to ONC201. Based on these findings, ONC212 warrants further development as a drug candidate. It is clear that therapeutic utility extends beyond ONC201 to include additional imipridones.

100 项与 Provid Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Provid Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

1

5

临床前

其他

1

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

DQ2/8 program (Provid Pharma)	乳糜泻更多	临床前
F11R program (Provid Pharma) ( F11R )	动脉粥样硬化更多	临床前
PV-267 ( HLA-A2 )	多发性硬化症更多	临床前
RNAP program (Provid Pharma) ( RNAP )	细菌感染更多	临床前
DR1/DR4 program (Provid Pharma) ( DR1 x DR4 )	类风湿关节炎更多	临床前